Category: Joint ventures/collaborations
-
U.S.-India Partnership to Develop Long Shelf-Life Tomato
Arcadia Biosciences Inc. in Davis, California, and Bioseed Research India Pvt. Ltd. in Hyderabad unveiled plans to develop a tomato with more durability and longer shelf life. Financial terms of the deal were not disclosed. Because of their perishable nature, many fresh fruits and vegetables — including tomatoes — are bred for durability and yield…
-
Intel Corp. to Fund Social Computing Research Center
Intel Corporation in Santa Clara, California will support a new research center on social computing, hosted by University of California at Irvine. The $12.5 million project is the seventh of the company’s Intel Science and Technology Centers (ISTCs) and includes partnerships with researchers at Cornell University, Georgia Tech, Indiana University, and New York University. ISTC-Social…
-
VTT, GE Healthcare to Partner on Alzheimer’s Biomarkers
VTT Research Centre in Espoo, Finland and GE Healthcare, a division of General Electric Company, will collaborate on research involving biomarkers for Alzheimer’s disease. The aim of the research is to validate one biomarker already discovered by VTT, as well as discover other early indicators of the disease. World Health Organization estimates some 18 million…
-
Merck Serono, Compugen to Form Toxicity Biomarkers Start-Up
Merck Serono, a division of the global pharmaceutical company Merck in Geneva, Switzerland and the drug discovery company Compugen in Tel Aviv, Israel have agreed to form Neviah Genomics, a new enterprise to develop biomarkers for the prediction of drug-induced toxicity. While some financial arrangements were revealed, the total value of the deal was not…
-
National Lab Opens Battery Manufacturing R&D Center
Oak Ridge National Laboratory in Tennessee, part of U.S. Department of Energy, has opened a research and development center for battery manufacturing. The lab says the facility is designed for open collaboration among participating companies, although the lab did not disclose which companies are taking part. The facility, which the lab says costs $3 million,…
-
NC State, Strasbourg Institutes to Advance Biomanufacturing
North Carolina State University in Durham and University of Strasbourg in France, along with the Alsace BioValley cluster in Europe, are forming Biomanufacturing Training and Education Center (BTEC) International, to provide educational and regulatory advisory services in the U.S. and Europe. BTEC International will initially combine the resources of NC State’s Golden LEAF Biomanufacturing Training…
-
Mobile Data Help Predict Displaced Populations in Haiti
Researchers at Karolinska Institutet in Stockholm, Sweden used data from a mobile phone company in Haiti to devise a system to predict population displacements when disaster strikes. Their findings appear online in in the journal Proceedings of the National Academy of Sciences (paid subscription required), and formed the basis of a service to help relief…
-
Roche, Seaside Therapeutics to Partner on Autism, Fragile X
Seaside Therapeutics in Cambridge, Massachusetts and the Swiss pharmaceutical company Roche will collaborate to develop treatments for autism spectrum disorders and fragile X syndrome. Financial terms of the agreement were not disclosed. Autism spectrum disorders and fragile X syndrome are neurodevelopmental disorders for which there are no effective treatments yet that address core symptoms. Autism…
-
Report: Few Biotechs Working on Neglected Diseases
A report by BIO Ventures for Global Health, a not-for-profit organization related to the Biotechnology Industry Organization (BIO), says only about five percent of the world’s biotechnology companies are developing new drugs, vaccines, or diagnostics against neglected diseases. The report, Biotechnology: Bringing Innovation to Neglected Disease Research and Development, is scheduled for release today at…
-
Merck, Ambrx to Partner on Biologics Candidate Development
Ambrx Inc., a biopharmaceutical company in La Jolla, California, will collaborate with the global pharmaceutical maker Merck, to design and develop biologic drug conjugates, antibodies connected to drug payloads that bind with disease cell targets. The deal has a value of up to $303 million for Ambrx. The agreement gives Merck worldwide rights to develop…